The inclusion of these documented TFs further validates our TF profiles and introduces 20 novel AD‐TFs and 32 novel NE‐TFs (Figure 1E; Tables S1 and S2, Supporting Information), which hold promise as significant players or therapeutic targets for PRAD and NEPC. This evidence concerns the gene TF and Alzheimer disease.